Center for Genomic Medicine, Desert Research Institute, Reno, NV 89512, USA.
Cancer Research Institute, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Int J Mol Sci. 2023 Aug 17;24(16):12870. doi: 10.3390/ijms241612870.
Obesity is a growing public health problem associated with increased risk of type 2 diabetes, cardiovascular disease, nonalcoholic fatty liver disease (NAFLD) and cancer. Here, we identify microRNA-22 (miR-22) as an essential rheostat involved in the control of lipid and energy homeostasis as well as the onset and maintenance of obesity. We demonstrate through knockout and transgenic mouse models that miR-22 loss-of-function protects against obesity and hepatic steatosis, while its overexpression promotes both phenotypes even when mice are fed a regular chow diet. Mechanistically, we show that miR-22 controls multiple pathways related to lipid biogenesis and differentiation. Importantly, genetic ablation of miR-22 favors metabolic rewiring towards higher energy expenditure and browning of white adipose tissue, suggesting that modulation of miR-22 could represent a viable therapeutic strategy for treatment of obesity and other metabolic disorders.
肥胖是一个日益严重的公共卫生问题,与 2 型糖尿病、心血管疾病、非酒精性脂肪性肝病(NAFLD)和癌症的风险增加有关。在这里,我们确定 microRNA-22(miR-22)是一种重要的变阻器,参与控制脂质和能量稳态以及肥胖的发生和维持。我们通过敲除和转基因小鼠模型证明,miR-22 功能丧失可预防肥胖和肝脂肪变性,而其过表达即使在小鼠喂食常规饮食时也可促进这两种表型。从机制上讲,我们表明 miR-22 控制与脂质生物发生和分化相关的多种途径。重要的是,miR-22 的遗传缺失有利于代谢重编程,增加能量消耗和白色脂肪组织的棕色化,表明 miR-22 的调节可能是治疗肥胖症和其他代谢紊乱的可行治疗策略。